You are here: Industry Insights > FDA

News List

Lupin Announces FDA Approval of Supplemental New Drug Application for Solosec (secnidazole) for the Treatment of Trichomoniasis drugs
July 07, 2021
Lupin announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) to expand the use of Solosec (secnidazole) to include the treatment of trichomoniasis in adults.
Recall of Chantix Due to Impurity americanpharmaceuticalreview
July 05, 2021
FDA is alerting patients and health care professionals to Pfizer’s voluntary recall of nine lots of the smoking cessation drug, varenicline (brand name Chantix), to the warehouse level.
FDA Approves Treatment Regimen for Most Prevalent Childhood Cancer americanpharmaceuticalreview
July 05, 2021
The FDA approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the ...
Nonprofit Covid Clinic Continues to Open Testing Locations Amid Delta Variant Spread prnewswire
July 05, 2021
As state, county, and local sponsored testing sites across the country are being shuttered, California-based COVID Clinic is heading in the opposite direction by adding new testing locations every week.
Alembic Pharma gets USFDA final approval for Nitrofurantoin Capsules, USP (Macrocrystals) expresspharma
July 02, 2021
The capsules are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.
Lupin gets USFDA approval of sNDA for SOLOSEC (secnidazole) to treat trichomoniasis expresspharma
July 02, 2021
SOLOSEC demonstrated a 92.2 per cent clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3 clinical trial.
FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma drugs
July 02, 2021
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen.
FDA Approves Component of Treatment Regimen for Most Common Childhood Cancer fda.gov
July 02, 2021
Today, the U.S. Food and Drug Administration approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients.
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines prnasia
July 01, 2021
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, announced that it has raised $73M in Series B financing.
Lupin gets tentative US FDA nod for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) tablets under PEPFAR expresspharma
July 01, 2021
TLD is recommended by WHO, USAID and PEPFAR as a preferred first-line treatment regimen for the treatment of HIV in adults and pediatric patients weighing at least 35 kg.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 365 366 Next page